VTRS - Viatris Inc
8.84
| Index: | S&P 500 | P/E: | - | EPS (ttm): | -3.18 | Insider Own: | 2.54% | Shs Outstand: | 1.19B | Perf Week: | 0.80% |
| Market Cap: | 10.38B | Forward P/E: | 3.62 | EPS next Y: | 2.44 | Insider Trans: | 0.20% | Shs Float: | 1.14B | Perf Month: | 19.62% |
| Income(ttm): | -3790.10M | PEG: | - | EPS next Q: | 0.55 | Inst Own: | 82.04% | Short Float: | 4.26% | Perf Quarter: | -18.15% |
| Revenue(ttm): | 14.26B | P/S: | 0.73 | EPS this Y: | -16.11% | Inst Trans: | -0.89% | Short Ratio: | 3.11 | Perf Half Y: | -31.63% |
| Book/sh: | 13.20 | P/B: | 0.67 | EPS next Y: | 9.73% | ROA: | -8.83% | Short Interest: | 48.71M | Perf Year: | -20.65% |
| Cash/sh: | 0.72 | P/C: | 12.19 | EPS next 5Y: | 0.65% | ROE: | -21.25% | 52W Range: | 6.85 - 13.55 | Perf YTD: | -29.00% |
| Dividend Est.: | 0.48 (5.40%) | P/FCF: | 5.45 | EPS past 5Y: | - | ROI: | -12.63% | 52W High: | -34.76% | Beta: | 0.89 |
| Dividend TTM: | 0.48 (5.43%) | Quick Ratio: | 0.86 | Sales past 5Y: | 6.93% | Gross Margin: | 38.88% | 52W Low: | 29.05% | ATR (14): | 0.35 |
| Dividend Ex-Date: | May 23, 2025 | Current Ratio: | 1.58 | EPS Y/Y TTM: | -6809.78% | Oper. Margin: | 5.76% | RSI (14): | 56.23 | Volatility: | 3.05% 3.40% |
| Employees: | 32000 | Debt/Eq: | 0.92 | Sales Y/Y TTM: | -6.88% | Profit Margin: | -26.57% | Recom: | 2.55 | Target Price: | 11.20 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.92 | EPS Q/Q: | -2808.28% | Payout: | - | Rel Volume: | 0.57 | Prev Close: | 8.79 |
| Sales Surprise: | 0.59% | EPS Surprise: | 1.65% | Sales Q/Q: | -11.28% | Earnings: | May 08 BMO | Avg Volume: | 15.65M | Price: | 8.84 |
| SMA20: | 4.81% | SMA50: | 3.91% | SMA200: | -19.17% | Undervalued: 26.7% | Volume: | 8,920,513 | Change: | 0.57% | |
Graham Classic formula value: -27.98
(P/E=8 * 1g) Min value: -24.7
(current P/E * 2g) Max value: -3.71
Average value: -18.8
About Viatris Inc
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.